The day pharma’s weight-loss gold rush intensified

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

‘I can't shake the anxiety about weight regain if I'm priced out of Mounjaro’: On life after GLP-1s

One writer felt she'd finally reached her bodily happy ever after via GLP-1 jabs. But with soaring prices and scientific unknowns on the horizon...now what?

Eli Lilly says weight-loss pill a candidate for speedy approval under new US program

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
EconoTimes

Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand

Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...

Lilly Makes Billions of Weight-Loss Pills Before US Approval

Eli Lilly & Co. has already produced billions of doses of its next-generation weight-loss pill, anticipating massive global ...

Eli Lilly readies billions of weight-loss pills ahead of U.S. approval

Eli Lilly (NYSE:LLY) has already manufactured billions of doses of its next-generation weight-loss pill, anticipating strong ...

Dawn of the weight-loss superpill: They'll be easier and cheaper to take than jabs. Now ANTONIA HOYLE reveals shock trial results and side-effects every dieter need…

The idea was beautifully simple. One pill taken daily to melt away those excess pounds. The new breed of GLP-1 oral ...
Le Lézard

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound

Eli Lilly and Company and Walmart Inc. today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect.
The Malaysian Reserve

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years

Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies TREMFYA® is the only ...